Trial Profile

A Single-arm, Open, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Recurrent or Metastatic Cervical Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iparomlimab/tuvonralimab (Primary)
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms DUBHE-C-206
Sponsors Qilu Pharmaceutical

Most Recent Events

15 Mar 2024 Status changed from recruiting to completed, according to a results presented in Qilu Pharmaceutical Media Release.
15 Mar 2024 Results presented in an Qilu Pharmaceutical Media Release.
15 Mar 2024 According to an Qilu Pharmaceutical Media Release, data from this trial was presented at the 25th European Society of Gynecological Oncology (ESGO) Conference (ESGO 2024) in Spain.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com